Table 2

Sensitivity of ES/PNET cells to chemotherapeutic agents after combined sequential treatments

ES/PNET cells were treated with progressive doses of doxorubicin (DXR) or vincristine (VCR) for 12–24 h and then were exposed to αIR3 MAb (1 μg/ml), or control MOPC-21 MAb (1 μg/ml), or suramin (250 μg/ml for TC-71 and LAP-35 cells; 100 μg/ml for SK-N-MC cells). Results represent the mean ± SE of triplicate experiments.
Cell linesTreatmentIC50 valuesa (ng/ml)Fold-increase in DXR and VCR sensitivity
TC-71DXR→medium21.2 ± 1.25
DXR→MOPC-21 MAb33.8 ± 2.52
DXR→αIR3 MAb0.016 ± 0.002b1325
DXR→suramin0.301 ± 0.056b70
VCR→medium1.38 ± 0.095
VCR→MOPC-21 MAb1.17 ± 0.042
VCR→αIR3 MAb0.34 ± 0.025b4
VCR→suramin0.15 ± 0.02b8
SK-N-MCDXR→medium5.9 ± 1.5
DXR→αIR3 MAb0.843 ± 0.04c7
DXR→suramin0.443 ± 0.02c13
VCR→medium0.466 ± 0.09
VCR+αIR3 MAb0.072 ± 0.01c6
VCR+suramin0.086 ± 0.005c5
LAP-35DXR→medium2.95 ± 0.15
DXR→αIR3 MAb0.008 ± 0.0002b369
DXR→suramin0.38 ± 0.04b8
VCR→medium2.5 ± 0.2
VCR+αIR3 MAb0.01 ± 0.008b250
VCR+suramin0.008 ± 0.002b312
  • a Drug concentration resulting in 50% inhibition of cell growth.

  • b P < 0.001; Student’s t test.

  • c P < 0.05; Student’s t test.